由于具有坚实的化学研究基础以及200亿美元的巨大财源,拜耳公司(Leverkeusen,西德)几乎可以在世界上任何一个地方开展研究工作。不过,该公司还是选择了美国作为建立分子生物学研究中心的据点。该公司在美国的保健子公司 Miles 的药物处已完成了座落于康州西哈文的研究中心的第一期工程。耗资3600万美元的建筑(包括设备)将用于分子生物 With a solid foundation in chemical research and a huge financial source of US$20 billion, Leverkeusen (West Germany) can conduct research almost anywhere in the world. However, the company chose the United States as a stronghold to establish a molecular biology research center. The company’s drug division at Miles, a health subsidiary in the United States, has completed the first phase of its research center in Xihaven, Connecticut. A $36 million building (including equipment) will be used for molecular biology